Professor Camille Carroll
Professor Edward Meinert
| Digital health technologies and self-efficacy in Parkinson's: a scoping review | 2025 |
|
Professor Camille Carroll
| Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial | 2025 |
|
Professor Camille Carroll
| A programme evaluation of 'First Steps': A peer-conceived, developed and led self-management intervention for people after a Parkinson's diagnosis | 2024 |
|
Professor Camille Carroll
Professor Lynn Rochester
| Accelerating Parkinson’s Disease drug development with federated learning approaches | 2024 |
|
Professor Camille Carroll
| Addressing Comorbidities in People with Parkinson's Disease: Considerations From An Expert Panel | 2024 |
|
Professor Camille Carroll
| Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease | 2024 |
|
Professor Lynn Rochester
Professor Camille Carroll
| Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials | 2024 |
|
Professor Alison Yarnall
Professor Camille Carroll
| Improving conversations about Parkinson’s dementia | 2024 |
|
Professor Camille Carroll
| Is SH3GL2 p.G276V the Causal Functional Variant Underlying Parkinson's Disease Risk at this Locus? | 2024 |
|
Professor Camille Carroll
| Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease | 2024 |
|
Dr Marie-Louise Zeissler
Sally Collins
Professor Camille Carroll
| Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson's Disease: An Evaluation Protocol | 2024 |
|
Emeritus Professor David Brooks
Professor Camille Carroll
Professor Nicola Pavese
| Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease | 2024 |
|
Professor Camille Carroll
| Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson's Disease Care Pathway: A Healthcare Improvement Initiative | 2024 |
|
Professor Camille Carroll
| Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial | 2024 |
|
Selina Boege
Madison Milne-Ives
Professor Edward Meinert
Professor Camille Carroll
| Self-Management Systems for Patients and Clinicians in Parkinson Care: Protocol for an Integrated Scoping Review, Product Search, and Evaluation | 2024 |
|
Selina Boege
Madison Milne-Ives
Ananya Ananthakrishnan
Professor Camille Carroll
Professor Edward Meinert
et al. | Self-Management Systems for Patients and Clinicians in Parkinson's Disease Care: A Scoping Review | 2024 |
|
Dr Mark Cookson
Professor Camille Carroll
| Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative | 2024 |
|
Professor Camille Carroll
| A modular, deep learning-based holistic intent sensing system tested with Parkinson’s disease patients and controls | 2023 |
|
Professor Camille Carroll
| An International Multi-Stakeholder Delphi Survey Study on the Design of Disease Modifying Parkinson's Disease Trials | 2023 |
|
Katie Bounsall
Madison Milne-Ives
Professor Camille Carroll
Professor Edward Meinert
| Artificial Intelligence Applications for Assessment, Monitoring, and Management of Parkinson Disease Symptoms: Protocol for a Systematic Review | 2023 |
|
Professor Camille Carroll
| Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9) | 2023 |
|
Professor Camille Carroll
| Blood biomarker-based classification study for neurodegenerative diseases | 2023 |
|
Professor Richard Walker
Professor Camille Carroll
| Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study | 2023 |
|
Professor Camille Carroll
| Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study | 2023 |
|
Professor Camille Carroll
| Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1) | 2023 |
|
Professor Camille Carroll
| Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2) | 2023 |
|
Professor Camille Carroll
| Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | 2023 |
|
Professor Camille Carroll
| Genome-wide Analysis of Motor Progression in Parkinson Disease | 2023 |
|
Dr Rufus Akinyemi
Professor Camille Carroll
| Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study | 2023 |
|
Professor Camille Carroll
Professor Edward Meinert
| Impact of digital technologies on self-efficacy in people with Parkinson's: a scoping review protocol | 2023 |
|
Professor Camille Carroll
| Incorporating usability evaluation into iterative development of an online platform to support research participation in Parkinson's disease: A mixed methods protocol | 2023 |
|
Dr Marie-Louise Zeissler
Professor Camille Carroll
| Investigating trial design variability in trials of disease-modifying therapies in Parkinson’s disease: a scoping review protocol | 2023 |
|
Professor Lynn Rochester
Dr Marie-Louise Zeissler
Professor Camille Carroll
| Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative | 2023 |
|
Dr Marie-Louise Zeissler
Professor Camille Carroll
Professor Lynn Rochester
Professor Alison Yarnall
Sally Collins
et al. | Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease | 2023 |
|
Professor Camille Carroll
| Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson’s disease | 2022 |
|
Professor Camille Carroll
| Challenges of Incorporating Digital Health Technology Outcomes in a Clinical Trial: Experiences from PD STAT | 2022 |
|
Professor Camille Carroll
| Co-designing Resources for Knowledge-Based Self-reflection for People Living with Parkinson's Disease to Better Enable Independent Living | 2022 |
|
Professor Camille Carroll
| Enhancing Trial Delivery in Parkinson's Disease: Qualitative Insights from PD STAT | 2022 |
|
Professor Camille Carroll
| Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial | 2022 |
|
Professor Lynn Rochester
Professor Camille Carroll
| Implications of research that excludes under-served populations | 2022 |
|
Professor Camille Carroll
Professor Nicola Pavese
| Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease | 2022 |
|
Madison Milne-Ives
Professor Camille Carroll
Professor Edward Meinert
| Self-management Interventions for People With Parkinson Disease: Scoping Review | 2022 |
|
Professor Edward Meinert
Professor Camille Carroll
| The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Nonmotor Symptoms in People With Parkinson Disease: Proposal for a Phase 1 Implementation Study | 2022 |
|
Kimberley Down
Dr Gary Nestor
Professor John O'Brien
Professor Camille Carroll
| A report from the NIHR UK working group on remote trial delivery for the COVID-19 pandemic and beyond | 2021 |
|
Professor Camille Carroll
| Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future? | 2021 |
|
Professor Camille Carroll
| Early Detection of Alzheimer's Disease with Blood Plasma Proteins Using Support Vector Machines | 2021 |
|
Professor Camille Carroll
Dr Silvia Del Din
Professor Alison Yarnall
Professor Lynn Rochester
| Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease: protocol for a multi-centre, randomised, double blind, parallel group, placebo controlled, Phase 3 trial, The 'Exenatide-PD3' study | 2021 |
|
Professor Camille Carroll
| Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease | 2021 |
|
